The adoption of Adoptive Cell Therapy Market has been increasing rapidly driven by the rising prevalence of cancer and increasing approvals of various adoptive cell therapy products. Adoptive cell therapy involves genetically modifying a patient's own immune cells to attack cancer cells. T cells isolated from patients are engineered to expressed receptors that make them recognize tumor antigens, which allow the cells to hunt and destroy cancer cells. Various types of cell therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy have been approved for the treatment of hematologic cancers. Furthermore, the number of ongoing clinical trials evaluating adoptive cell therapies for solid tumors has increased significantly over the past few years.
The Global Adoptive Cell Therapy Market is estimated to be valued at US$ 6,903.93 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Adoptive Cell Therapy are Broadcom, Celeno Communications, Infineon Technologies, Espressif Systems Shanghai Co Ltd, GCT Semiconductor Inc., I&C Technology, Intel Corporation, MediaTek, Inc., Microchip Technology Inc. The rising prevalence of cancer and strong product pipeline are fueling the demand for adoptive cell therapies. Major companies are focuses on strategic collaborations and acquisitions to strengthen their product portfolio and expand their global footprint.
Growing demand in the market is attributed to increase in research funding for clinical trials by both government as well as private organizations. In addition, favorable regulatory environment and approval of various CAR T-cell therapies have accelerated research and development activities.
Key companies are expanding their presence in developing regions such as Asia Pacific and Latin America owing to high untreated patient population and rising healthcare expenditure.
Market Drivers
Increase in incidence of cancer worldwide especially hematologic cancers such as leukemia and lymphoma is a key factor propelling the Adoptive Cell Therapy Market Growth. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. Additionally, advancements in genetic engineering techniques enabling development of novel therapy molecules are further augmenting the market demand. Growing awareness about advantages of targeted therapies along with strong product pipeline will continue to boost the adoptive cell therapy industry expansion over the forecast period.
The current geopolitical tensions are impacting the growth of the adoptive cell therapy market. Many countries are facing economic hardships and budget constraints due to rising inflation, supply chain issues and other economic challenges arising due to the pandemic and ongoing conflicts. This is limiting the investments in advanced healthcare technologies including adoptive cell therapies in various regions. However, certain countries are prioritizing healthcare even in difficult times to provide better treatment outcomes to patients.
The market is witnessing high degree of consolidation with key players expanding to new markets through strategic partnerships and collaborations. While North America and Europe currently hold major share of the adoptive cell therapy market value due to presence of advanced healthcare facilities and supporting reimbursement policies, players are exploring opportunities in Asia Pacific and Middle Eastern markets through technology transfers and license agreements. This will help boost the market access and affordability of these promising therapies in high growth territories over the coming years.
Geographically, North America accounts for the largest share of the global adoptive cell therapy market currently, owing to strong government support and high healthcare spending. Within North America, the US dominates the regional market and is expected to continue leading over the forecast period supported by favorable reimbursement policies and availability of advanced treatment options. Europe holds the second largest market share on back of increasing research on cancer immunotherapy and cell-based treatments.
Asia Pacific region is poised to witness the fastest growth in the adoptive cell therapy market over the next decade. This can be attributed to rising healthcare expenditure, growing incidences of cancer and other target diseases, and increasing adoption of advanced treatment therapies in major Asian markets such as China, India, Japan and South Korea. Additionally, initiatives toward building research infrastructure and strengthening local manufacturing base by global industry players will help drive faster market evolution in Asia Pacific.
Get more insights on Adoptive Cell Therapy Market
